TAT Technologies Q3-2026: Strong Growth but Cash Conversion Remains Key

What happened

TAT Technologies reported Q3-2026 revenue growth of 20% year-over-year, with operating income up 72% and adjusted EBITDA up 61%, demonstrating continued operating leverage and execution on its backlog. Management indicated the improved gross margin profile is likely sustainable in the near term, which addresses a key watch item from our prior analysis. However, the company acknowledged that recent inventory investments temporarily reduced operating cash flow, reinforcing the ongoing gap between accounting earnings and free cash flow. The balance sheet remains strong, providing flexibility for organic or acquisition-driven growth, but the stock still trades at premium multiples that leave little margin for error. While the quarter supports the growth narrative, it does not yet resolve our core concern about durable cash conversion.

Implication

The Q3-2026 results show that TAT Technologies continues to convert its backlog into double-digit revenue growth and expanding margins, which supports the bull case. However, the temporary reduction in operating cash flow due to inventory investments highlights that working capital remains a drag on free cash flow, a key metric we monitor. With the stock up significantly over the past year and trading at elevated P/E and EV/EBITDA multiples, the market already prices in sustained growth and improved cash conversion. We would need to see several consecutive quarters of positive free cash flow and improving inventory turns before shifting to a more constructive stance. Until then, we maintain a WAIT rating, watching for evidence that earnings quality catches up with reported profits.

Thesis delta

The thesis remains largely unchanged: TATT is a quality niche operator with strong growth, but free cash flow has yet to match earnings, and the valuation leaves little room for disappointment. The Q3-2026 results indicate that margin improvements may be sticky, which slightly reduces the risk of margin compression in the near term. However, the continued working capital investment offsets this positive, and we see no reason to upgrade the stock from WAIT at this juncture.